Reports Q4 revenue $43.9M, consensus $38.0M. “I am thrilled to be joining Quanterix (QTRX) at a time when the company is well-positioned to deliver long-term growth,” said Everett Cunningham, President & CEO of Quanterix. “During the fourth quarter, we exceeded our revenue expectations, we continued to move the company closer to profitability, and we achieved key milestones in our Alzheimer’s Diagnostics business. With most of the major integration milestones now behind us, our focus now turns to driving consistent profitable revenue growth and achieving cash flow breakeven performance in 2026. My immediate focus is on spending time with the Quanterix team, customers, shareholders, and partners as I evaluate the Company’s strategy and future potential and ensure that we have the resources, support and capabilities to deliver on our operational priorities. I am extremely optimistic for what the future holds for Quanterix.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QTRX:
- Quanterix (QTRX) Q4 Earnings Cheat Sheet
- Quanterix submits FDA 510(k) for Alzheimer’s disease blood test
- Quanterix: Leadership Transition and Akoya Integration Drive Strategic Uncertainty Behind Maintained Hold Rating
- Quanterix Announces CEO Transition to Drive Growth
- Quanterix names Everett Cunningham president, CEO
